hematology-2017-scientifictracks-abstracts

9 / 22

Page 28
Notes:
conferenceseries .com
Volume 8, Issue 5 (Suppl) J Blood Disord Transfus, an open access journal
ISSN:2155-9864 Hematology 2017
November 08-09, 2017
November 08-09, 2017 | Las Vegas, USA
11th International Conference on
Hematology & Hematological Oncology
Integrating new treatment options into the management of adult ITP
James Granfortuna
University of North Carolina Medical Center at Chapel Hill, USA
Treatment of Steroid resistant ITP in adults can be challenging in patients who are actively bleeding. The majority of novel
therapies that have been developed in the last few years including anti CD 20 monoclonal antibody therapy (Rituximab)
and thrombopoietic growth factors, romiplostim and eltombopag, take time to work. Combinations of active agents may
accelerate the response rate. Splenectomy and the use of immunosuppressive agents may still have an important role in the
acute management. A case of resistant ITP will be discussed in the context of currently available treatment modalities.
Biography
James Granfortuna MD FACP graduated from Mount Sinai School of Medicine in 1980 and completed a Hematology Oncology Fellowship at the State University
of NY Health Sciences Center in Syracuse NY in 1987. He is board certified in both specialties. He is currently an Associate Professor of Clinical Medicine at the
Cone Health Internal Medicine Teaching Program in Greensboro, NC.
James Granfortuna, J Blood Disord Transfus 2017, 8:5 (Suppl)
DOI: 10.4172/2155-9864-C1-028